GUCY2F (guanylate cyclase 2F, also known as ROS-GC1 or GUCYA3) is a membrane-bound particulate guanylate cyclase specifically expressed in cone photoreceptor cells of the mammalian retina. It catalyzes the conversion of GTP to cGMP, the second messenger that maintains the cyclic nucleotide-gated (CNG) channels in the open state in the dark, thereby regulating the membrane potential and signal transduction of cone photoreceptors. GUCY2F is unique among membrane guanylate cyclases in its cone-specific expression pattern and its regulation by a distinct set of calcium-sensor proteins, the guanylate cyclase-activating proteins (GCAPs), which respond to the calcium changes that occur during the phototransduction cycle. Mutations in GUCY2F cause progressive cone dystrophy and are associated with achromatopsia in some cases. While primarily a retinal protein, GUCY2F provides insights into the broader biology of cyclic GMP signaling, calcium homeostasis, and photoreceptor survival mechanisms that are relevant to understanding neurodegeneration.
| GUCY2F Protein |
|---|
| Protein Name | Retinal guanylate cyclase 2F (ROS-GC1) |
| Gene | GUCY2F (GUCYA3) |
| UniProt ID | [P51841](https://www.uniprot.org/uniprot/P51841) |
| Molecular Weight | ~120 kDa |
| Subcellular Localization | Cone outer segment disc membranes |
| Protein Family | Membrane-bound guanylate cyclase (particulate GC) family |
| Expression | Cone photoreceptors (retina-specific) |
GUCY2F is a single-pass transmembrane protein of approximately 1,100 amino acids with the characteristic modular architecture of the membrane guanylate cyclase family:
¶ Protein Domains
- Extracellular domain (residues 1-480): N-terminal ligand-binding and regulatory region — contains multiple conserved motifs, disulfide bond-forming domains (CTP-like), and sites for GCAP interaction
- Transmembrane helix (residues 481-503): Single membrane-spanning domain anchoring the protein to disc membrane
- Kinase homology domain (KHD) (residues 504-700): Resembles protein kinases but lacks catalytic activity — modulates cyclase activity in response to regulatory inputs
- Cyclase catalytic domain (residues 701-1100): C-terminal region that forms the active site — homodimerization brings two catalytic domains together to form the functional cyclase
The catalytic domain contains the signature residues required for GTP binding and cyclization. Dimerization (via the catalytic domains) is required for activity — GUCY2F functions as a homodimer, with each monomer contributing to the catalytic pocket.
GUCY2F is the primary source of cGMP production in the cone phototransduction cascade:
- Dark state: In the dark, cGMP levels are high, keeping cyclic nucleotide-gated (CNG) channels open. Na+ and Ca2+ influx through CNG channels (via CNGA3/CNGB3 channels) maintains the dark current and membrane depolarization.
- Light activation: Light causes a conformational change in cone opsins (photopsins), activating transducin (GNAT2) and PDE6. PDE6 hydrolyzes cGMP, rapidly lowering cGMP concentration.
- Channel closure: Reduced cGMP closes CNG channels, reducing Na+/Ca2+ influx and causing membrane hyperpolarization.
- Recovery: Lower intracellular Ca2+ (due to reduced influx) activates GCAPs (primarily GCAP2), which activate GUCY2F. Increased cGMP synthesis reopens CNG channels, restoring the dark state.
GUCY2F is uniquely regulated by cone-specific guanylate cyclase-activating proteins:
- GCAP2 (GUCA2B): Primary activator of GUCY2F in cones. At high Ca2+ (dark), GCAP2 is calcium-bound and inactive. At low Ca2+ (light), GCAP2 releases Ca2+ and undergoes conformational change, activating GUCY2F.
- GCAP1 (GUCA2A): Contributes to GUCY2F regulation in some cone types.
- GCAP3 (GUCA2C): Expressed in a subset of cones, may provide additional regulation.
This Ca2+-dependent feedback loop is the central recovery mechanism in cone phototransduction. The GCAP-GUCY2F module acts as a "light sensor" that dynamically adjusts cGMP synthesis to match the degree of illumination.
GUCY2F is the cone ortholog of GUCY1B (ros gc), the rod guanylate cyclase:
| Feature |
GUCY1B (Rod GC) |
GUCY2F (Cone GC) |
| Expression |
Rod outer segments |
Cone outer segments |
| Primary GCAP |
GCAP1, GCAP2 |
GCAP2 (predominant) |
| Activation kinetics |
Slower recovery |
Faster recovery |
| Ca2+ sensitivity |
GCAP-dependent |
GCAP-dependent |
| Pathologies |
RP (if mutated) |
Cone dystrophy, achromatopsia |
cGMP produced by GUCY2F acts through two main effector pathways:
- Cyclic nucleotide-gated (CNG) channels: The primary target — cGMP directly binds to and opens CNG channels (CNGA3 + CNGB3 subunits in cones)
- cGMP-dependent protein kinase G (PRKG): Less prominent in cones than in rods — may contribute to signaling cascades and adaptation
Mutations in GUCY2F cause progressive cone dystrophy :
- Phenotype: Progressive loss of cone photoreceptor function, with relative preservation of rod function early in disease
- Symptoms: Decreased visual acuity, impaired color vision (particularly red-green discrimination), photophobia, and sensitivity to light
- Inheritance: Usually autosomal recessive
- Progression: Variable rate of cone degeneration; peripheral visual field typically preserved longer than central vision
- Electrophysiology: Severely reduced or absent cone ERG responses with relatively normal rod responses
Some GUCY2F mutations contribute to achromatopsia (rod monochromacy):
- Complete color blindness with reduced visual acuity, nystagmus, and photophobia from birth
- Typically autosomal recessive
- Often involves mutations in multiple cone phototransduction genes (GUCY2F, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H)
While GUCY1B is more commonly associated with RP, GUCY2F mutations can also cause retinal degeneration:
- Usually later onset and milder phenotype than rod-specific GC mutations
- Progressive cone-rod dystrophy pattern
Although GUCY2F is retina-specific, it offers insights into neurodegeneration mechanisms:
The cGMP signaling pathway parallels GUCY2F biology in neuronal contexts—but differs in important ways:
| Feature |
Soluble GC (sGC) |
Particulate GC (GUCY2F) |
| Activation |
Nitric oxide (NO) |
GCAP proteins (Ca2+-dependent) |
| Location |
Cytosol |
Membrane-bound |
| Regulation |
Heme-based NO sensing |
Dimerization & GCAP binding |
| Brain expression |
Neurons, glia |
Limited (retina primarily) |
Alzheimer's Disease:
- Reduced neuronal cGMP correlates with cognitive decline
- PDE5 upregulation reduces cGMP available for synaptic plasticity
- NO signaling—precursor to cGMP—is dysregulated in AD vasculature
- cGMP-raising agents (PDE5 inhibitors) improve memory in models
Parkinson's Disease:
- D1 receptor coupling to cAMP/cGMP is disrupted
- nNOS activation in dopaminergic nuclei
- cGMP-gated channels in olfactory bulb—relevant to PD smell loss
Stroke and Ischemia:
- Ischemic preconditioning involves cGMP pathway activation
- NO donors are neuroprotective pre-conditioners
- sGC stimulators reduce infarct size in models
| Drug |
Target |
Mechanism |
Neurodegeneration Application |
| Sildenafil |
PDE5 |
Inhibits cGMP hydrolysis |
Investigational for AD, stroke |
| Tadalafil |
PDE5 |
Longer half-life |
Investigational for PD |
| Riociguat |
sGC stimulator |
NO-independent activation |
Investigational for vascular cognitive impairment |
| Vericiguat |
sGC stimulator |
NO-independent activation |
Cardiovascular, cognitive |
The GUCY2F-GCAP calcium feedback module is a model for understanding calcium dysregulation—a central feature of neurodegeneration:
- NMDA receptor overactivation: Leads to calpain activation
- ER calcium depletion: Aβ forms Ca2+-permeable pores
- Mitochondrial Ca2+ overload: Triggers mPTP opening
- Calpain-cdk5 activation: p25 generation drives tau pathology
- L-type Ca2+ channels: Cav1.3 vulnerability of dopaminergic neurons
- Mitochondrial Ca2+: Complex I deficiency affects Ca2+ handling
- ER stress: Ca2+ dysregulation triggers UPR
- Calpain activation: Contributes to α-synuclein aggregation
GCAPs are neuronal calcium sensor (NCS) family members. Other NCS proteins:
- Recoverin: Photoreceptor-specific, involved in dark adaptation
- GCAP1/2/3: Retinal GCAPs activating guanylate cyclases
- Calmodulin: Ubiquitous Ca2+ sensor, regulates many enzymes
- NCS1 (NCS1): Neuronal calcium sensor 1
Therapeutic targeting of calcium sensors is an emerging strategy.
The mechanisms of cone degeneration in GUCY2F mutations inform understanding of neuronal death:
- Loss of calcium homeostasis: Dysregulated Ca2+ → calpain/caspase activation
- Protein aggregation: Misfolded protein triggers ER stress
- Metabolic failure: Cyclic nucleotide depletion disrupts function
- Oxidative stress: High metabolic demand creates vulnerability
Gene therapy approaches for GUCY2F-related cone dystrophy translate to neurodegeneration:
- AAV-mediated delivery: Standard CNS gene therapy vector
- Cone-specific promoters: Inform brain region-specific promoters
- CRISPR correction: Base editing for point mutations
- Optogenetic approaches: Light-sensitive channels bypass damage
GUCY2F integrates with multiple components of the phototransduction cascade:
Light → Rhodopsin (RHO) → GNAT2 (Transducin) → PDE6 → cGMP decrease
↓
CNG channels close
↓
Ca2+ decrease via Na+/Ca2+ exchanger
↓
GCAP activation → GUCY2F activation
↓
cGMP increase
↓
CNG channels open (recovery)
- cGMP-gated, allows Na+ and Ca2+ influx
- Pore opening requires cGMP binding
- Conductance modulated by Ca2+/calmodulin
- Less prominent in cones vs. rods
- May regulate adaptation mechanisms
- PRKG1 in many brain regions
GCAPs sense Ca2+ via EF-hand domains:
- High Ca2+ (dark): Ca2+-GCAP binds GUCY2F but does not activate → channels close → hyperpolarization
- Low Ca2+ (light): Ca2+-free GCAP activates GUCY2F → cGMP synthesis → channels open → depolarization
This negative feedback loop is the basis of phototransduction recovery.
- Gucy2f knockout: Cone phototransduction defect, cone ERG loss
- Humanized GUCY2F knock-in: Modeling cone dystrophy mutations
- GCAP double knockout: Severe cone degeneration
- 661W cone cell line: Murine cone photoreceptor cells expressing GUCY2F
- ARPE-19 cells: Human retinal pigment epithelium, GCAP studies
- Stem cell-derived cones: Patient-specific modeling
- Recombinant GUCY2F: Protein for structural/functional studies
- GCAP fusion proteins: Ca2+ sensitivity assays
- cGMP analogs: 8-Br-cGMP, 8-pCPT-cGMP
The cGMP signaling pathway parallels GUCY2F biology in neuronal contexts:
- Natriuretic peptide receptors (NPR-A, NPR-B): Membrane GCs in brain that respond to ANP/BNP peptides
- Soluble guanylate cyclases (sGC): NO-activated GCs in neurons — regulate synaptic plasticity, learning, and memory
- cGMP-dependent kinases (PRKG1, PRKG2): Neuronal signaling downstream of cGMP
- Phosphodiesterases (PDE5, PDE6, PDE9): cGMP degradation — PDE5 inhibitors (sildenafil, tadalafil) are neuroprotective in some contexts
The GUCY2F-GCAP calcium feedback module is a model for understanding calcium dysregulation:
- Calcium dysregulation in AD/PD: Impaired calcium homeostasis is a central feature of neurodegeneration
- GCAP-like proteins in brain: Some neuronal proteins share functional similarity with GCAPs in calcium sensing
- Calcium-dependent proteases: Calpains are activated by calcium influx and contribute to neurodegeneration — similar calcium sensitivity governs GUCY2F regulation
The mechanisms of cone degeneration in GUCY2F mutations inform understanding of neuronal death:
- Loss of calcium homeostasis: Dysregulated Ca2+ leads to activation of calpains and caspases
- Protein aggregation: Misfolded GUCY2F may trigger ER stress and unfolded protein response
- Metabolic failure: cGMP depletion leads to CNG channel closure, disrupting ionic balance
- Oxidative stress: Cone photoreceptors have high metabolic demand and are vulnerable to oxidative damage
Gene therapy approaches developed for GUCY2F-related cone dystrophy may translate to neurodegeneration:
- AAV-mediated gene replacement: Delivering functional GUCY2F to cone cells
- Genome editing: CRISPR-based correction of disease-causing mutations
- Optogenetic approaches: Bypassing damaged cones with light-sensitive channel expression
| Partner |
Interaction Type |
Functional Consequence |
| GCAP2 (GUCA2B) |
Ca2+-dependent activation |
Primary regulator of cyclase activity |
| GCAP1 (GUCA2A) |
Activator |
Contribute to GUCY2F regulation |
| GCAP3 (GUCA2C) |
Activator |
Species/retina-specific regulation |
| CNGA3 |
Channel co-assembly |
cGMP-gated ion influx |
| CNGB3 |
Channel co-assembly |
Channel localization and regulation |
| Transducin (GNAT2) |
Downstream signaling |
PDE6 activation reduces cGMP |
| PDE6 |
Downstream signaling |
Catalyzes cGMP hydrolysis |
| Recoverin |
Modulator |
Inactivates GNAT2 |
| S100B |
Calcium binding |
May modulate GCAP function |
- Gene therapy: AAV vectors carrying GUCY2F show promise in animal models of cone dystrophy
- CRISPR correction: Base editing and prime editing approaches for point mutations
- Structural studies: Cryo-EM structures of GUCY2F-GCAP complexes would inform mechanism
- Cone regeneration: Understanding GUCY2F regulation may aid cone cell replacement strategies
- Cross-disease relevance: cGMP signaling insights may inform therapies for brain cGMPopathies